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ABSTRACT 
Background: 
Nomogram could estimate individualized prognosis in papillary thyroid carcinoma (PTC). We 
aimed to create and validate a new nomogram and compare it with other published nomograms 
using a large patient cohort. 
Methods: 
Eight-hundred and forty-nine PTC patients with ≥7 years follow-up were randomly assigned to 
the development (n=425) and validation (n=424) groups. The former was used for developing a 
nomogram for disease-specific survival (DSS) while the latter was for validating the nomogram 
by discrimination (or Area under Curve (AUC)). AUC of the newly-developed nomogram was 
compared to other published nomograms. 
Results: 
The 5-year and 10-year risk of dying from PTC were 1.4% and 3.3% respectively while dying 
from non-PTC-related causes were 2.3% and 5.1% respectively. The new nomogram was 
developed from age, tumor size, multifocality, nodal status and distant metastases. The 
discrimination was excellent (AUC (95%CI) for 5- and 10-year DSS were 0.896 (0.683-0.971) 
and 0.919 (0.871-0.967), respectively). Its predictability was similar to other published 
nomograms (p>0.05). Based on the new nomogram, a total score of < 28 meant 99.72% chance 
of surviving from PTC at 10 years while a score of ≥28 meant 9.09% chance of dying from PTC 
at 10-years. 
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Conclusions: 
Using variables from the current TNM staging system, a new nomogram was developed. It 
exhibited excellent discriminatory ability and accuracy in predicting 10-year DSS relative to 
other published nomograms. However, given the excellent prognosis of PTC, the new nomogram 
was better at ruling out than predicting PTC-related death. Further validation by an external 
cohort is required.
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INTRODUCTION 
Differentiated thyroid carcinoma is the most common type of thyroid carcinoma and its 
incidence has doubled over the past two decades1,2. Although it is generally associated with an 
excellent outcome, its prognosis depends on the presence of certain clinicopathologic 
characteristics3,4. Numerous staging systems have been available for stratifying risk in papillary 
(PTC) and follicular thyroid carcinoma and the American Joint Committee on Cancer (AJCC) 
Tumor Node Metastasis (TNM) staging system has been the most accurate3,4. However, although 
it works well for a patient population, it is less useful in predicting prognosis for an individual 
patient. Nomogram is a powerful clinical tool designed in predicting outcome of an individual 
patient by utilizing multiple clinical variables5,6. A well-balanced nomogram could provide 
individualized estimation of prognosis and help counselling cancer patients’ management 
selection and optimizing therapeutic approaches5,6. To PTC, this could potentially mean tailoring 
the extent of surgery, decision on radioiodine (RAI) ablation afterwards and follow-up 
intensity3,4. To our knowledge, there have been few nomograms reported in the literature 
designed for thyroid cancers7-9. Furthermore, given the fact that most were developed from 
population-based cohorts, tumor variables described appeared less conventional and therefore, 
were more difficult to apply clinically than those used in the existing TNM staging or other risk-
stratification systems10. Furthermore, since they were developed from the Caucasians population, 
they may be less applicable to our predominantly ethnic-Chinese population. Given these issues, 
we aimed to develop and validate a new nomogram and then compare it with other nomograms 
published in the literature using a large patient cohort from at our institution. Since we 
anticipated that a considerable number of patients may die from non-PTC related causes, a 
competing-risk model was used for analysis.
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PATIENTS AND METHODS 
Patient cohort 
From 1970 - 2006, 1038 consecutive patients with PTC underwent total or near-total 
thyroidectomy in our institution. Of these, 35 (3.4%) with incomplete patient data and 154 
(14.8%) with occult microcarcinoma (<1cm) were excluded. Therefore, 849 (81.8%) were 
included. All patients had a minimum follow-up of 7 years and were managed by a standardized 
protocol described previously11. In brief, total or near-total thyroidectomy was preferred. 
Simultaneous therapeutic central (level VI) +/- lateral (levels II-V) selective neck dissection was 
performed for clinically-proven nodal metastasis. Prophylactic central neck dissection was not 
routinely performed. Decision for RAI ablation was based on factors such as tumor size > 1.5cm, 
nodal metastasis, age >45 years old, extrathyroidal extension, residual disease and distant 
metastasis. To ensure updated patient status, a careful search in the territory-wide Clinical 
Management System (CMS) was performed on all 849 patients. The CMS links up all public 
hospitals and covers over 90% of all inpatient medical records in the whole territory. The latest 
date of follow-up or date of death and the cause of death were retrieved from the CMS. All 
causes of death were later confirmed by examination of the medical record, autopsy report and / 
or death certificate. Disease-specific survival (DSS) was defined as the time from PTC diagnosis 
to the date when the patient died of PTC. All relevant clinicopathological and perioperative data 
were collected prospectively after 1994 and regularly updated in a computerized database. The 
present study protocol was approved by the local institutional review board. 
Development, validation and comparison of the new nomogram 
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Our patient cohort was randomly divided into two groups, namely the development set (n=425) 
and the validation (n=424) set. The former was used to develop a risk algorithm or nomogram 
for 5- and 10-year DSS using a proportional sub-distribution hazards model. This model 
accounted for the competing-risk of dying from non-PTC related causes. The validation set was 
used for testing out the newly-developed nomogram by discrimination and calibration. Lastly, 
the performance of the newly-developed nomogram was compared with other published 
nomograms in the literature using the validation set. 
Published nomograms and their interpretation 
Using the search terms (“nomogram”, “predictive model” and “thyroid cancer”) at the Scopus 
and Medline (PubMed) electronic databases, three independent nomograms were found7-9 but 
since only two were applicable to PTC, only two were selected for comparison. The first 
nomogram was reported by Yang et al8 using the Surveillance, Epidemiology and End Results 
(SEER) data program. They found age (years), tumor size (mm), extent of primary tumor 
(localized, regional or distant), lymph node involvement (none, regional or distant) and histology 
(papillary, follicular, medullary and anaplastic) to be significant independent variables. For this 
study, we assumed “distant extent of primary tumor” and “distant lymph node involvement” 
were equivalent to distant metastases by the TNM system. The second nomogram was reported 
by Pathak et al.7 using a large patient cohort from the Manitoba (Canada) Cancer Registry. Age 
(years), sex (male or female), histology (papillary, non-papillary or medullary), distant 
metastases (yes or no), tumor stage (T1, T2, T3 or T4) and post-treatment residual disease (yes 
or no) were significant independent variables. Since our validation set comprised PTC only, the 
score on “histology” in both nomograms was given a score of zero. However, since both papers 
did not provide a more precise numeric cut-off value for each independent variable, the first 
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and/or corresponding authors were contacted directly and asked for more detailed information 
regarding their nomogram before analysis.  
Statistical analysis 
Descriptive statistics of baseline characteristics between development and validation sets were 
compared using independent t-test for continuous variables and Chi-square test for categorical 
variables.  
Using the development set, we established a multivariable competing-risk subhazard models for 
predicting risk of dying from PTC, account for the competing-risks of dying from non-PTC-
related causes based on Fine and Gray modelling approach12. Significant risk factors with p<0.10 
in stepwise competing-risk subhazard model were retained in the point system. Each risk factor 
was assigned a weighting in the point system using the respective β-coefficients multiplied by 10 
and rounded to the nearest whole number. The risk score for each subject is the sum of risk score 
contributed by each risk factor identified by the final point system. A final simple point system 
was constructed in scoring and predicting an individual 5-year and 10-year risk dying from PTC. 
Youden’s index was used to determine the optimal cutoff value in predicting of the development 
of DSS in the next 5 or 10 years. 
Data from the validation set were entered into each risk algorithm / nomogram to produce area 
under the receiver-operating characteristic curve (AUC). This was a measure of discrimination. 
The AUCs were compared using the method of Delong test13. A calibration plot was applied to 
plot the observed probabilities of PTC-related death against the nomogram-predicted 
probabilities of PTC-related death. Accuracy was also measured by means of sensitivity, 
specificity, positive predictive value and negative predictive value using the optimal cut-off. All 
statistical analyses were performed using SPSS version 18.0 (SPSS, Inc., Chicago, IL, USA) and 
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the STATA software version 13 (STATA Corp, College Station, Texas).
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RESULTS 
Our patient cohort comprised mostly women (79.4%) and ethnic Chinese (91.8%). The mean age 
was 45.6 ± 16.8 years while the mean tumor size was 2.2 ± 1.7cm. There were 210 (24.7%) 
patients who presented with clinically palpable cervical nodal metastases and 26 (3.0%) who 
presented with distant metastases. After a median follow-up of 17.1 (7.2 – 47.2) years, 61 (7.2%) 
patients died of PTC, 47 (5.5%) patients died of non-thyroidal malignancy and 73 (8.6%) died of 
a non-cancer (i.e. medical or natural) cause. The 5-year, 10-year and 15-year risks of dying from 
PTC were 1.4%, 3.3% and 4.4%, respectively while from non-PTC-related cause were 2.3%, 
5.1% and 8.5%, respectively. At the time of analysis, 30 (3.5%) patients were still alive with 
detectable local and/or distant diseases while 64 (7.5%) patients were reverted to “disease-free” 
after treatment.  
Table 1 shows a comparison of clinicopathological factors and patient status between the 
development and validation sets. Essentially, age at diagnosis, sex, tumor size, frequency of 
extrathyroidal extension, nodal status, distant metastases, completion of resection and RAI were 
comparable between the two sets. However, tumor multifocality was significantly more frequent 
in the development set than the validation set (35.5% vs. 27.6%, p=0.013). The number of PTC-
related deaths in development and validation sets was 34 (8.0%) and 27 (6.4%), respectively. 
The 10-year risk of dying from PTC was comparable between the two sets (4.2% vs. 3.3%, 
p=0.367). 
Table 2 shows the significant prognostic risk factors and their assigned score for 5- and 10-year 
DSS. Male sex, extrathyroidal extension, completion of resection and RAI were not significant 
factors and therefore, not shown. Only age at diagnosis, tumor size, tumor multifocality (defined 
≥2 tumor foci in ipsilateral lobe), nodal status and distant metastases were significant 
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independent factors for both 5- and 10-year DSS. Age at diagnosis <25 years, primary tumor size 
<2.0cm, absence of multifocality, no nodal metastases (N0/Nx) and no distant metastases were 
given a risk score of zero while others were given a score ranging between 2 – 21. Therefore, the 
maximum total score for the 5-year and 10-year DSS nomogram were 60 and 62, respectively. 
Table 3 shows the respected accuracy and discrimination of the three nomograms when the 
development and validation sets were entered. Using data from the development set, the new 
nomogram had an AUC (95%CI) in predicting 5- and 10-year DSS of 0.900 (0.846-0.954) and 
0.896 (0.827-0.965), respectively while when the validation set was used, the discriminatory 
ability was maintained at a similar level (AUC (95%CI) for 5- and 10-year DSS were 0.896 
(0.822 – 0.971) and 0.919 (0.871-0.967), respectively). This demonstrated the new nomogram 
produced good discrimination in an independent set and confirmed its potential for exportability. 
AUCs for predicting 10-year DSS in Yang’s nomogram and Pathak’s nomogram were also 
excellent (0.892 and 0.859, respectively), although they appeared lower than that of the new 
nomogram (0.919). Nevertheless, in pairwise comparison of ROC curves, the difference between 
the new nomogram and Yang’s (p=0.462), between the new nomogram and Pathak’s (p=0.220) 
or between Yang’s and Pathak’s (p=0.616) were not statistically significant. Using the respective 
optimal cut-off value, each nomogram produced its best sensitivity, specificity, positive 
predictive value (PPV) and negative predictive value (NPV). The new nomogram appeared to 
have comparable sensitivity, specificity, PPV and NPV as the other two published nomograms. 
One finding worth noting was that all the NPVs were significantly higher than PPVs and this 
implied the fact that all nomograms were better at ruling out than predicting PTC-related death. 
Based on the new nomogram, for a total score of 28 or less, the overall chance of surviving from 
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PTC at 10 years was 99.72% while if a total score was 28 or more, the overall chance of dying 
from PTC at 10-years was 9.09%. 
Figure 1 shows the calibration plot for predicting 5-year and 10-year DSS. Since all the points 
were close to the 45-degree line, this indicated good agreement between the predicted and 
observed 5-year and 10-years DSS. 
Figure 2a shows the newly-constructed nomogram for predicting 5-year risk of dying from PTC 
and  Figure 2b shows the nomogram for predicting 10-year risk of dying from PTC using the 
development set (n=425). Each parameter has been assigned a score and the sum of these scores 
provides a predicted risk of dying from PTC in 5 or 10 years ranging 0.1% to 50%.
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DISCUSSION 
Our data showed that the 10-year probabilities of dying from PTC in the development and 
validation sets were 4.2% and 2.3%, respectively (or an overall rate of 3.3%). These rates were 
similar to those reported from the two previous population-based cohort studies7,8. In the SEER 
database8, the 10-year probability of dying from thyroid cancer was 3.0% while in the Manitoban 
program, the 10-year probability of dying from PTC was 3.2%7. The overall 10-year probability 
of dying from non-PTC related causes was also similar to that reported from the SEER data 
(5.1% vs.5.9%, respectively)8, although such data was not available from the Manitoban program 
[7]. Therefore, despite being a single institutional study, the overall probabilities of dying from 
PTC and non-PTC-related causes were remarkably similar to those reported from population-
based studies. Secondly, over time, the probability of dying from non-PTC related causes was 
roughly twice that of dying from PTC itself8. The latter finding highlighted the importance and 
the rationale of using a competing-risk model in the development of a nomogram. 
One point worth noting regarding the new and the other two nomograms was that because of the 
excellent prognosis of PTC with few patients dying from PTC after a long period of time, it was 
significantly easier for either of the 3 nomograms to rule out PTC-related death than to predict it. 
For example, using the new nomogram, if a patient had an aggregate score of 28 or less, the 
overall chance of not dying from PTC was close to 100% while the chance of dying from PTC if 
the aggregate score was 28 or more was only 9.09% (or roughly 1 in 10). Therefore, despite 
using an optimal cut-off, our new nomogram could still only correctly predict a patient with a 
higher score may die in the future in less than 10% of the time while it could predict with 
certainty that a patient with a lower score will not die from PTC.  
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Relative to the other two nomograms,7,8 we believe we have developed a nomogram which is 
more practical and friendlier for clinicians to use. This is because most of the prognostic 
variables (such as age, tumor size, nodal status and distant metastases) incorporated in the new 
nomogram appeared similar to the variables used in the existing AJCC TNM staging and other 
risk-stratification systems3 and therefore, it would be easier to apply in actual clinical practice. 
However, unlike the TNM staging system, the new nomogram provides a better prediction for 
individual patients, based on statistical modeling. Interestingly, the presence of tumor 
multifocality turned out to be a significant independent factor in the new nomogram but not 
considered in the current TNM staging system or other two published nomograms. One possible 
reason for this discrepancy might have been because tumor multifocality is often accurately not 
recorded or coded in population-based cancer registries and therefore, not available for 
evaluation in most population-based studies. However, it is worth highlighting that numerous 
studies have found tumor multifocality to be an important prognostic factor of PTC-related death 
in clinically-significant (> 1cm) PTC14-16. 
Residual disease after thyroidectomy was found to be an important prognostic variable in one 
nomogram7 but not in ours and the other nomogram. Although some existing stratification 
systems also considered residual disease to be an important prognostic factor3,4, the variable 
“completeness of resection” did not turn out significant in our multivariate analysis. One possible 
reason might have been because this factor was largely based on the surgeon’s and pathologist’s 
judgement and so, it may vary between cases making this variable a less reliable factor. 
In terms of nomogram performance, although not statistically significant, our model appeared to 
have better discrimination and accuracy in predicting 10-year DSS than the other two models7,8. 
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However, this should not be a surprise as the independent data set (or the validation set) used 
was essentially derived from the same patient cohort as the development set and therefore, it was 
not truly externally validated. Nevertheless, given that our nomogram might be easier to apply 
clinically than other two nomograms, our nomogram might be a better clinical tool for predicting 
PTC-related survival. 
Despite these findings, we acknowledged certain shortcomings. Since this was a single 
institution study, it may have insufficient power to identify some true prognostic variables. Also 
unlike other population-based analyses, it was subjected to institutional and referral biases. 
Nevertheless, we believe our data are of better quality than many population-based databases as 
data were updated prospectively and therefore the chance of misdiagnosis and death 
misclassification was small. We also acknowledge the fact that even though our nomogram was 
validated by a separate cohort, this cohort came from the same population and therefore, strictly 
speaking, our nomogram was not externally validated. Nevertheless, using an external cohort (i.e. 
patients managed outside our institution) in validating ours and other two nomograms could be 
done in the future. Also we would acknowledge the fact that our nomogram did not predict 
relapses which may arguably be a clinically more-relevant outcome than cancer-related deaths10. 
However, since response to initial therapy is an important factor in evaluating relapses, many 
patients from the earlier period might not be included for such analysis17. Lastly, since this 
nomogram was purely based on clinical factors, perhaps the addition of molecular markers may 
further improve the prediction accuracy18,19. 
Conclusion 
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Over time, almost twice as many patients with PTC died of non-PTC-related causes than of PTC 
alone. Using variables similar to those in current TNM staging system, we have developed a new 
nomogram using more clinically refined and applicable variables in predicting 5- and 10-year 
DSS. Relative to the other two published nomograms, the new nomogram had excellent 
discriminatory ability and accuracy in predicting 10-year DSS. However, due to the excellent 
prognosis of PTC, the new nomogram was better at ruling out than predicting PTC-related death. 
Perhaps, future studies could validate this new nomogram with an external cohort. 
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Table 1. A comparison of clinicopathological factors and patient status between the development and validation sets  
 Development set (n=425) Validation set (n=424) Entire cohort (n=849) p-value* 
Age at diagnosis  (years) 
- < 25 
- ≥ 25 and < 45 
 - ≥45 – 65 
- > 65 
 
42 (9.9) 
183 (43.1) 
128 (30.1) 
72 (16.9) 
 
45 (10.6) 
172 (40.6) 
139 (32.8) 
68 (16.0) 
 
87 (10.2) 
355 (41.8) 
267 (31.4) 
140 (16.5) 
0.799 
Sex 
- Male 
- Female 
 
91 (21.4) 
334 (78.6) 
 
84 (19.8) 
340 (80.2) 
 
175 (20.6) 
674 (79.4) 
0.564 
Tumor size (cm) 
- < 2.0 
- ≥ 2.0 and < 4.0 
- ≥ 4.0 
 
208 (48.9) 
134 (31.5) 
83 (19.5) 
 
222 (52.3) 
136 (32.1) 
66 (15.6) 
 
430 (50.6) 
270 (31.8) 
149 (17.6) 
0.308 
Tumor multifocality 
- Absent 
 
274 (64.5) 
 
307 (72.4) 
 
581 (68.4) 
0.013 
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- Present 151 (35.5) 117 (27.6) 268 (31.6) 
Extrathyroidal extension 
- Absent 
- Present 
 
278 (65.4) 
147 (34.6) 
 
298 (70.3) 
126 (29.7) 
 
576 (67.8) 
273 (32.2) 
0.138 
Nodal status# 
- None (N0/Nx) 
- N1a 
- N1b 
 
254 (59.8) 
67 (15.8) 
104 (24.5) 
 
278 (65.6) 
52 (12.3) 
94 (22.2) 
 
532 (62.7) 
119 (14.0) 
198 (23.3) 
0.176 
Distant metastases 
- Absent 
- Present 
 
412 (96.9) 
13 (3.1) 
 
411 (96.9) 
13 (3.1) 
 
823 (96.9) 
26 (3.1) 
0.995 
Completeness of resection 
- Complete 
- Incomplete 
 
400 (94.1) 
25 (5.9) 
 
396 (93.4) 
28 (6.6) 
 
796 (93.8) 
53 (6.2) 
0.644 
Radioiodine ablation 
- Not given 
- Given 
 
161 (37.9) 
264 (62.1) 
 
186 (43.9) 
238 (56.1) 
 
347 (40.9) 
502 (59.1) 
0.166 
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Patient status at analysis 
- Alive without recurrence 
- Alive with recurrence 
- Alive with other malignancy 
- Died of PTC 
- Died of other malignancy 
- Died of medical disease 
 
312 (73.4) 
16 (3.8) 
2 (0.5) 
34 (8.0) 
25 (5.9) 
36 (8.5) 
 
323 (76.2) 
14 (3.3) 
1 (0.2) 
27 (6.4) 
22 (5.2) 
37 (8.7) 
 
571 (67.3) 
30 (3.5) 
3 (0.4) 
61 (7.2) 
47 (5.5) 
73 (8.6) 
0.714 
Categorical variables are expressed as number (percentage) 
PTC = papillary thyroid carcinoma 
*comparison between development and validation sets 
#by 7th edition TNM staging system 
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Table 2. Prognostic risk factors and their assigned score influencing 5- and 10-year disease-specific survivals in the proportional sub-
distribution hazard competing risks model 
 5-year disease-specific survival 10-year disease-specific survival 
SHR 95% CI p-
value 
ß-
coeff. 
Assigned 
Score 
SHR 95% CI p-
value 
ß-
coeff. 
Assigned 
Score 
Age at diagnosis (yrs) 
- < 25 
- ≥ 25 and < 45 
 - ≥45 – 65 
- > 65 
 
1 
1.244 
5.116 
8.088 
 
- 
0.200–7.724 
0.995–26.320 
1.540-42.485 
 
- 
0.815 
0.051 
0.014 
 
- 
0.218 
1.632 
2.090 
 
0 
2 
16 
21 
 
1 
1.284 
5.617 
8.515 
 
- 
0.213-7.754 
1.103-28.597 
1.651-43.917 
 
- 
0.785 
0.038 
0.011 
 
- 
0.249 
1.726 
2.142 
 
0 
2 
17 
21 
Tumor size (cm) 
- < 2.0 
- ≥ 2.0 and < 4.0 
- ≥ 4.0 
 
1 
1.798 
2.488 
 
- 
0.693-4.663 
0.999-6.193 
 
- 
0.227 
0.050 
 
- 
0.587 
0.911 
 
0 
6 
9 
 
1 
1.730 
2.303 
 
- 
0.657-4.555 
0.856-6.196 
 
- 
0.267 
0.099 
 
- 
0.548 
0.834 
 
0 
5 
8 
Tumor multifocality 
- Absent 
- Present 
 
1 
2.030 
 
- 
0.994-4.142 
 
- 
0.052 
 
- 
0.708 
 
0 
7 
 
1 
2.010 
 
- 
0.920-4.393 
 
- 
0.080 
 
- 
0.698 
 
0 
7 
Nodal status# 
- None (N0/Nx) 
 
1 
 
- 
 
- 
 
- 
 
0 
 
1 
 
- 
 
- 
 
- 
 
0 
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- N1a 
- N1b 
1.760 
3.114 
0.502-6.169 
1.404-6.904 
0.377 
0.005 
0.565 
1.136 
6 
11 
1.752 
3.328 
0.489-6.278 
1.483-7.468 
0.389 
0.004 
0.561 
1.202 
6 
12 
Distant metastases 
- Absent 
- Present 
 
1 
3.485 
 
- 
1.347-9.013 
 
- 
0.010 
 
- 
1.248 
 
0 
12 
 
1 
4.090 
 
- 
1.313-12.745 
 
- 
0.015 
 
- 
1.409 
 
0 
14 
Abbreviation: SHR = Subhazard ratio; ß-coeff. = ß-coefficient 
#based on 7th edition TNM staging system 
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Table 3. A comparison of discrimination (as measured by area under the curve (AUC)) and accuracy between nomograms using the 
development set and validation set  
Risk algorithms Area under the curve 
(AUC) (95%CI) 
Optimal 
cutoff value  
Sensitivity 
(%) 
Specificity 
(%) 
Positive 
predictive 
value (%) 
Negative 
predictive 
value (%) 
 Applying to the development set (n=425) 
Our model 
- 5-year DSS 
- 10-year DSS 
 
0.900 (0.846-0.954) 
0.896 (0.827-0.965) 
 
30 
28 
 
100.0 
94.12 
 
79.14 
78.02 
 
7.77 
13.01 
 
100.0 
99.67 
 Applying to the validation set (n=424) 
Our model 
- 5-year DSS 
- 10-year DSS 
Yang et al. [8]+ 
- 10-year DSS 
Pathak et al. [7]* 
- 10-year DSS 
 
0.896 (0.822-0.971) 
0.919 (0.871-0.967) 
 
0.892 (0.822-0.962) 
 
0.859 (0.757-0.961) 
 
30 
28 
 
101.6 
 
75 
 
75.00 
88.89 
 
88.89 
 
77.78 
 
84.29 
80.34 
 
76.90 
 
82.56 
 
4.35 
9.09 
 
7.84 
 
8.97 
 
99.72 
99.72 
 
99.69 
 
99.42 
+the model was based on variables such as age, tumor size, extent of primary tumor (localized, regional or distant) and lymph node 
involvement (none, regional or distant) 
*the model was based on variables such as age, sex, presence of distant metastases, tumor stage (T1 to T4) and post-treatment residual 
tumor
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LEGENDS 
 
Figure 1. The calibration curve for predicting 5-year and 10-year disease-specific survival. 
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Figure 2. The two new prognostic nomogram for predicting 5-year and 10-year risk of dying 
from papillary thyroid carcinoma 
